Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of GC012F, a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B-cell Maturation Antigen in Chinese Participants With Relapsed or Refractory AL Amyloidosis

NCT07250269 is registered in ClinicalTrials.gov with Gracell Biotechnologies (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT07250269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07250269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of GC012F, a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B-cell Maturation Antigen in Chinese Participants With Relapsed or Refractory AL Amyloidosis
Lead sponsor
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
October 29, 2025
Completion date
November 24, 2028
Enrollment
9 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory al amyloidosis